Mary-Ellen Taplin, MD, FASCO, is a medical oncologist and clinical investigator specializing in genitourinary oncology. She is a Professor of Medicine at Harvard Medical School, an Institute Physician at Dana-Farber Cancer Institute, and Chair of the Executive Committee for Clinical Research at Dana-Farber. Her clinical focus includes genitourinary medical oncology, systemic and hormone-based cancer therapeutics, and clinical trial-based care. Dr. Taplin’s research interests center on translational oncology, mechanisms of treatment response and resistance, and androgen receptor biology and biomarker-directed therapeutics. She serves as Co-Leader of the Prostate Cancer Program at Harvard Cancer Center and as Principal Investigator for the Prostate Cancer Clinical Trial Consortium. Her achievements have been recognized with election as a Fellow of the American Society of Clinical Oncology, the Claire W. and Richard P. Morse Research Award, the Ellen and Stephen Fine Award for Outstanding Teaching in Cancer Medicine, and the Dana-Farber Cancer Center Medical Oncology Teaching Award. Dr. Taplin earned her MD from the University of Massachusetts Medical School. She completed her internal medicine residency and chief medical residency at the University of Massachusetts Medical Center, followed by a hematology/oncology fellowship at Beth Israel Hospital and Harvard Medical School.
Professor
Medical School
1982 – 1986
Residency
1986 – 1990
Fellowship
1990 – 1993